Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20534742 | 0.91 | SCN9A (0.57) | SCN9A | |
| SCHEMBL17982223 | 0.88 | SCN9A (0.48) | SCN9A | |
| SCHEMBL17982393 | 0.87 | SCN9A (0.51) | SCN9A | |
| SCHEMBL20534731 | 0.83 | SCN9A (0.54) | SCN9A | |
| SCHEMBL20534169 | 0.82 | SCN9A (0.53) | SCN9A | |
| SCHEMBL20534428 | 0.81 | SCN9A (0.61) | SCN9A | |
| SCHEMBL20534693 | 0.81 | SCN9A (0.45) | SCN9A | |
| SCHEMBL17982365 | 0.81 | SCN9A (0.55) | SCN9A | |
| SCHEMBL20534191 | 0.79 | SCN9A (0.58) | SCN9A | |
| SCHEMBL17982221 | 0.78 | SCN9A (0.60) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256449-B1 | SODIUM CHANNEL BLOCKERS | IN THERAPEUTICS (KR) | 2022-05-04 | — | — | EP | claimed |
| CN-107108517-B | Sodium channel blockers | 株式会社大熊制药 | 2021-05-07 | — | — | CN | claimed |
| US-10590078-B2 | Sodium channel blockers | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2020-03-17 | — | — | US | claimed |
| US-20180297948-A1 | SODIUM CHANNEL BLOCKERS | IN THERAPEUTICS (KR) | 2018-10-18 | — | — | US | claimed |
| EP-3256449-B1 | SODIUM CHANNEL BLOCKERS | IN THERAPEUTICS (KR) | 2022-05-04 | — | — | EP | disclosed |
| CN-107108517-B | Sodium channel blockers | 株式会社大熊制药 | 2021-05-07 | — | — | CN | disclosed |
| US-10590078-B2 | Sodium channel blockers | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2020-03-17 | — | — | US | disclosed |
| US-20180297948-A1 | SODIUM CHANNEL BLOCKERS | IN THERAPEUTICS (KR) | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590078-B2 | Sodium channel blockers | SCN7A, SCN1A, SCN1B | SCN9A 9/4885 |
| US-20180297948-A1 | SODIUM CHANNEL BLOCKERS | SCN7A, SCN1A, SCN1B | SCN9A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.